Generation of multifunctional murine monoclonal antibodies specifically directed to the VP1unique region protein of human parvovirus B19

Immunobiology

Volumn 213, Issue 6, 2008, Pages 511-517

  Drechsler, Maik D ^a   Obermeier, Ingrid ^a   Döring, Yvonne ^a   Lackner, Karl J ^a   Modrow, Susanne ^b   von Landenberg, Philipp ^a  

^a UNIVERSITY MEDICAL CENTER MAINZ   (Germany)

^b UNIVERSITY OF REGENSBURG   (Germany)

Author keywords

Human parvovirus B19; Monoclonal antibody; Phospholipase A2 like activity; VP1u; VP1unique region protein

Indexed keywords

MONOCLONAL ANTIBODY; PHOSPHOLIPASE A2; PROTEIN VP1; RECOMBINANT PROTEIN; VIRUS PROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BAGG ALBINO MOUSE; CONTROLLED STUDY; DIAGNOSTIC VALUE; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME LINKED IMMUNOSORBENT ASSAY; HYBRIDOMA CELL CULTURE; IMMUNIZATION; IMMUNOFLUORESCENCE TEST; MOUSE; NONHUMAN; PARVOVIRUS INFECTION; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN SECRETION; SPLEEN CELL; VIRUS REPLICATION; WESTERN BLOTTING;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIBODIES, VIRAL; CAPSID PROTEINS; HUMANS; MICE; MICE, INBRED BALB C; PARVOVIRUS B19, HUMAN; PHOSPHOLIPASES A2; RECOMBINANT PROTEINS;

EID: 44349101871     PISSN: 01712985     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.imbio.2007.12.003     Document Type: Article

References (31)

1. Anderson M.J., Jones S.E., Fisher-Hoch S.P., Lewis E., Hall S.M., Bartlett C.L., Cohen B.J., Mortimer P.P., and Pereira M.S. Human parvovirus, the cause of erythema infectiosum (fifth disease)?. Lancet 1 (1983) 1378
2. Barah F., Vallely P.J., Chiswick M.L., Cleator G.M., and Kerr J.R. Association of human parvovirus B19 infection with acute meningoencephalitis. Lancet 358 (2001) 729-730
3. Brown T., Anand A., Ritchie L.D., Clewley J.P., and Reid T.M. Intrauterine parvovirus infection associated with hydrops fetalis. Lancet 2 (1984) 1033-1034
4. Bultmann B.D., Klingel K., Sotlar K., Bock C.T., Baba H.A., Sauter M., and Kandolf R. Fatal parvovirus B19-associated myocarditis clinically mimicking ischemic heart disease: an endothelial cell-mediated disease. Hum. Pathol. 34 (2003) 92-95
5. Corcoran A., Doyle S., Waldron D., Nicholson A., and Mahon B.P. Impaired gamma interferon responses against parvovirus B19 by recently infected children. J. Virol. 74 (2000) 9903-9910
6. Corman L.C., and Dolson D.J. Polyarteritis nodosa and parvovirus B19 infection. Lancet 339 (1992) 491
7. Cossart Y.E., Field A.M., Cant B., and Widdows D. Parvovirus-like particles in human sera. Lancet 1 (1975) 72-73
8. Cotmore S.F., McKie V.C., Anderson L.J., Astell C.R., and Tattersall P. Identification of the major structural and nonstructural proteins encoded by human parvovirus B19 and mapping of their genes by procaryotic expression of isolated genomic fragments. J. Virol. 60 (1986) 548-557
9. Dingli D., Pfizenmaier D.H., Arromdee E., Wennberg P., Spittell P.C., Chang-Miller A., and Clarke B.L. Severe digital arterial occlusive disease and acute parvovirus B19 infection. Lancet 356 (2000) 312-314
10. Dorsch S., Kaufmann B., Schaible U., Prohaska E., Wolf H., and Modrow S. The VP1-unique region of parvovirus B19: amino acid variability and antigenic stability. J. Gen. Virol. 82 (2001) 191-199
11. Dorsch S., Liebisch G., Kaufmann B., von Landenberg P., Hoffmann J.H., Drobnik W., and Modrow S. The VP1 unique region of parvovirus B19 and its constituent phospholipase A2-like activity. J. Virol. 76 (2002) 2014-2018
12. Drago F., Semino M., Rampini P., and Rebora A. Parvovirus B19 infection associated with acute hepatitis and a purpuric exanthem. Br. J. Dermatol. 141 (1999) 160-161
13. Enders G., Dotsch J., Bauer J., Nutzenadel W., Hengel H., Haffner D., Schalasta G., Searle K., and Brown K.E. Life-threatening parvovirus B19-associated myocarditis and cardiac transplantation as possible therapy: two case reports. Clin. Infect. Dis. 26 (1998) 355-358
14. Franssila R., Auramo J., Modrow S., Mobs M., Oker-Blom C., Kapyla P., Soderlund-Venermo M., and Hedman K. T helper cell-mediated interferon-gamma expression after human parvovirus B19 infection: persisting VP2-specific and transient VP1u-specific activity. Clin. Exp. Immunol. 142 (2005) 53-61
15. Gigler A., Dorsch S., Hemauer A., Williams C., Kim S., Young N.S., Zolla-Pazner S., Wolf H., Gorny M.K., and Modrow S. Generation of neutralizing human monoclonal antibodies against parvovirus B19 proteins. J. Virol. 73 (1999) 1974-1979
16. Hemauer A., Beckenlehner K., Wolf H., Lang B., and Modrow S. Acute parvovirus B19 infection in connection with a flare of systemic lupus erythematodes in a female patient. J. Clin. Virol. 14 (1999) 73-77
17. Lehmann H.W., Kuhner L., Beckenlehner K., Muller-Godeffroy E., Heide K.G., Kuster R.M., and Modrow S. Chronic human parvovirus B19 infection in rheumatic disease of childhood and adolescence. J. Clin. Virol. 25 (2002) 135-143
18. Lu J., Zhi N., Wong S., and Brown K.E. Activation of synoviocytes by the secreted phospholipase A2 motif in the VP1-unique region of parvovirus B19 minor capsid protein. J. Infect. Dis. 193 (2006) 582-590
19. 2+ entry by human parvovirus B19 capsid protein VP1. J. Virol. 80 (2006) 11370-11380
20. Moore T.L., Bandlamudi R., Alam S.M., and Nesher G. Parvovirus infection mimicking systemic lupus erythematosus in a pediatric population. Semin. Arthritis Rheum. 28 (1999) 314-318
21. Naides S.J., Scharosch L.L., Foto F., and Howard E.J. Rheumatologic manifestations of human parvovirus B19 infection in adults. Initial two-year clinical experience. Arthritis Rheum. 33 (1990) 1297-1309
22. Ozawa K., and Young N. Characterization of capsid and noncapsid proteins of B19 parvovirus propagated in human erythroid bone marrow cell cultures. J. Virol. 61 (1987) 2627-2630
23. Ozawa K., Ayub J., Hao Y.S., Kurtzman G., Shimada T., and Young N. Novel transcription map for the B19 (human) pathogenic parvovirus. J. Virol. 61 (1987) 2395-2406
24. Reid D.M., Reid T.M., Brown T., Rennie J.A., and Eastmond C.J. Human parvovirus-associated arthritis: a clinical and laboratory description. Lancet 1 (1985) 422-425
25. Rosenfeld S.J., Yoshimoto K., Kajigaya S., Anderson S., Young N.S., Field A., Warrener P., Bansal G., and Collett M.S. Unique region of the minor capsid protein of human parvovirus B19 is exposed on the virion surface. J. Clin. Invest. 89 (1992) 2023-2029
26. Scheurlen W., Ramasubbu K., Wachowski O., Hemauer A., and Modrow S. Chronic autoimmune thrombopenia/neutropenia in a boy with persistent parvovirus B19 infection. J. Clin. Virol. 20 (2001) 173-178
27. Serjeant G.R., Serjeant B.E., Thomas P.W., Anderson M.J., Patou G., and Pattison J.R. Human parvovirus infection in homozygous sickle cell disease. Lancet 341 (1993) 1237-1240
28. Tovari E., Mezey I., Hedman K., and Czirjak L. Self limiting lupus-like symptoms in patients with parvovirus B19 infection. Ann. Rheum. Dis. 61 (2002) 662-663
29. von Landenberg P., Lehmann H.W., Knoll A., Dorsch S., and Modrow S. Antiphospholipid antibodies in pediatric and adult patients with rheumatic disease are associated with parvovirus B19 infection. Arthritis Rheum. 48 (2003) 1939-1947
30. Zadori Z., Szelei J., Lacoste M.C., Li Y., Gariepy S., Raymond P., Allaire M., Nabi I.R., and Tijssen P. A viral phospholipase A2 is required for parvovirus infectivity. Dev. Cell 1 (2001) 291-302
31. Zuffi E., Manaresi E., Gallinella G., Gentilomi G.A., Venturoli S., Zerbini M., and Musiani M. Identification of an immunodominant peptide in the parvovirus B19 VP1 unique region able to elicit a long-lasting immune response in humans. Viral Immunol. 14 (2001) 151-158